Global Breast Cancer Predictive Genetic Testing Market Size By Type (High Penetrant Genes, Intermediate Penetrant Genes), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to...

The Global Breast Cancer Predictive Genetic Testing Market was valued at USD 3.9 billion in 2023 and is projected to reach USD 10.6 billion by 2031, growing at a CAGR of 13.2% during the forecast period from 2023 to 2031. The increasing awareness of hereditary breast cancer, rising adoption of personalized medicine, and ongoing advancements in genomic technologies are key factors driving market growth. Predictive genetic testing for breast cancer helps identify individuals at higher risk due to gene mutations such as BRCA1 and BRCA2, enabling preventive interventions and early treatment strategies.

Drivers

1. Growing Prevalence of Hereditary Breast Cancer

With breast cancer remaining one of the most common cancers among women globally, hereditary factors are gaining attention. Genetic mutations, particularly in BRCA1 and BRCA2, significantly increase lifetime risk, thus driving the demand for predictive genetic testing.

2. Rising Demand for Personalized Medicine

The healthcare sector’s pivot towards personalized medicine is a major driver. Predictive genetic testing allows for tailored prevention, monitoring, and treatment strategies, making it an essential tool in modern oncology.

3. Technological Advancements in Genomic Testing

Next-generation sequencing (NGS), improved bioinformatics, and AI-powered analytics are transforming genetic testing. Faster turnaround times, reduced costs, and higher accuracy are propelling market adoption.

Restraints

1. High Cost and Limited Insurance Coverage

Despite technological advances, the cost of predictive genetic tests can be prohibitive for many individuals. Limited reimbursement policies in several regions further hamper market penetration.

2. Ethical and Psychological Concerns

Genetic testing carries significant ethical implications. Psychological impacts from positive test results, privacy concerns, and potential genetic discrimination can discourage test adoption.

Opportunity

1. Expansion in Emerging Markets

Increased government support for cancer screening and rising awareness in emerging economies like India, China, and Brazil present untapped growth opportunities for genetic testing providers.

2. Integration of AI and Big Data in Genomics

Leveraging AI for predictive analytics and risk modeling enhances the utility of genetic data. Companies integrating AI-powered platforms with testing services are likely to see greater demand.

Market by System Type Insights

Based on system type, the BRCA1/BRCA2 Gene Testing segment held the largest share in 2023. The strong correlation between BRCA mutations and breast cancer risk has made this test the cornerstone of predictive genetic screening. However, the Multi-Gene Panel Testing segment is anticipated to grow at the fastest rate, offering a broader genetic landscape and identifying less common mutations associated with breast cancer.

Market by End-use Insights

In terms of end-use, the Hospitals and Oncology Clinics segment emerged as the largest contributor in 2023. These institutions offer comprehensive genetic counseling, testing, and treatment services. The Direct-to-Consumer (DTC) segment is gaining traction, driven by increased health awareness and growing availability of at-home testing kits.

Market by Regional Insights

North America dominated the global breast cancer predictive genetic testing market in 2023 due to its advanced healthcare infrastructure, widespread awareness, and strong presence of leading genetic testing companies. Asia-Pacific is projected to witness the highest growth during the forecast period, supported by rising cancer incidence rates, government screening initiatives, and expanding access to genetic testing.

Competitive Scenario

Key players in the market include Myriad Genetics, Invitae Corporation, 23andMe, F. Hoffmann-La Roche Ltd., Illumina Inc., Thermo Fisher Scientific, Color Genomics, Ambry Genetics, GeneDx, and Quest Diagnostics. These companies are investing in R&D, partnerships, and technological innovations to enhance their offerings.

2023: Myriad Genetics expanded its genetic testing platform with new AI-based risk prediction tools for breast cancer.

2024: Invitae launched a low-cost multigene panel for hereditary cancer screening targeting underserved markets.

2025: 23andMe received FDA approval for its new BRCA1/2 direct-to-consumer test update with enhanced risk analysis.

Scope of Work – Global Breast Cancer Predictive Genetic Testing Market

Key Market Developments

2023: Myriad Genetics released AI-enhanced breast cancer risk prediction tools integrated into electronic health records.

2024: 23andMe launched a user-friendly mobile app enabling consumers to understand and track their genetic health risks.

2025: F. Hoffmann-La Roche Ltd. partnered with regional oncology centers to offer subsidized multigene panel testing in Southeast Asia.

FAQs

1) What is the current market size of the Global Breast Cancer Predictive Genetic Testing Market?

The market was valued at USD 3.9 billion in 2023.

2) What is the major growth driver of the Global Breast Cancer Predictive Genetic Testing Market?

The primary growth driver is the increasing prevalence of hereditary breast cancer and the adoption of personalized medicine.

3) Which is the largest region during the forecast period in the Global Breast Cancer Predictive Genetic Testing Market?

North America is the largest region during the forecast period.

4) Which segment accounted for the largest market share in the Global Breast Cancer Predictive Genetic Testing Market?

The BRCA1/BRCA2 Gene Testing segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Breast Cancer Predictive Genetic Testing Market?

Key players include Myriad Genetics, Invitae Corporation, 23andMe, Roche, Illumina, and Thermo Fisher Scientific.